FDA Approval: Ceritinib for the Treatment of Metastatic Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Clinical Cancer Research

• Publication date

  2015-03-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-14-3157PMID 25754348
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Future options for ALK-positive non-small cell lung cancer.

  2015cited by this paper
• Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses.

  2015cited by this paper
• U.S. Food and Drug Administration Approval: Crizotinib for Treatment of Advanced or Metastatic Non–Small Cell Lung Cancer That Is Anaplastic Lymphoma Kinase Positive

  2014cited by this paper
• Molecular Pathways Molecular Pathways : Resistance to Kinase Inhibitors and Implications for Therapeutic Strategies

  2014cited by this paper
• Ceritinib in ALK-rearranged non-small-cell lung cancer.

  2014cited by this paper
• The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.

  2014cited by this paper
• CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.

  2013cited by this paper
• The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer.

  2013cited by this paper
• New targetable oncogenes in non-small-cell lung cancer.

  2013cited by this paper
• Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

  2012cited by this paper
• Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer

  2012cited by this paper
• ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.

  2012cited by this paper
• CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 22-554 CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW(S)

  2011cited by this paper
• Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.

  2011cited by this paper
• CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.

  2011cited by this paper
• New driver mutations in non-small-cell lung cancer.

  2011cited by this paper
• Critical aspects of the Bayesian approach to phase I cancer trials

  2008cited by this paper
• Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

  2007cited by this paper
• Cancer phase I clinical trials: efficient dose escalation with overdose control.

  1998cited by this paper
• Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis.

  1988cited by this paper

• Rational design of dual ALK inhibitors: scaffolds and strategies to circumvent drug resistance

  2026cites this paper
• FDA-Approved Pyrimidine-Containing Drugs: Synthesis and Clinical Application.

  2025cites this paper
• Mechanistic models position ceritinib as a nuclear integrity disrupting therapy in pediatric liver tumors

  2025cites this paper
• Real-World Clinical Oncology Outcomes Associated with the Accelerated Approval Pathway

  2025cites this paper
• Oligoethylene Phosphoramidate‐Based Kinase Inhibitor Prodrugs – Solubility, Enzyme Inhibition, and Hydrolysis

  2025cites this paper
• Substrate-controlled regioselective C(sp2)-H sulfonylation of ortho-aminophenols.

  2025cites this paper
• ALK inhibitors against resistance in non-small cell lung cancer: an 18 year medical arms race.

  2025cites this paper
• FDA-approved small molecule kinase inhibitors for cancer treatment (2001-2015): Medical indication, structural optimization, and binding mode Part I.

  2024cites this paper
• Population pharmacokinetics and exposure–response analyses of SAF-189s in Chinese patients with ALK+/ROS1+ non-small cell lung cancer

  2024cites this paper
• Arrhythmia Challenges in Cardio-Oncology: High-Risk Therapies, Management, and Anticoagulation.

  2024cites this paper
• A Phosphoramidate Prodrug Platform: One-Pot Amine Functionalization of Kinase Inhibitors with Oligoethylene Glycol for Improved Water-Solubility.

  2024cites this paper
• Amino Acid Metabolism Subtypes in Neuroblastoma Identifying Distinct Prognosis and Therapeutic Vulnerabilities.

  2024cites this paper
• Artificial Neural Network Models for Solution Concentration Measurement during Cooling Crystallization of Ceritinib

  2024cites this paper
• Atrioventricular re-entrant tachycardia and atrioventricular node re-entrant tachycardia in a patient with cancer under chemotherapy: a case report and literature review

  2024cites this paper
• Update of Diagnosis and Targeted Therapy for ALK+ Inflammation Myofibroblastic Tumor

  2023cites this paper
• Cardiac Arrhythmias in Patients Treated for Lung Cancer: A Review

  2023influential citation
• Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario

  2023cites this paper
• Risks of cardiovascular toxicities associated with ALK tyrosine kinase inhibitors in patients with non-small-cell lung cancer: a meta-analysis of randomized control trials

  2023cites this paper
• From ASCEND-5 to ALUR to ALTA-3, an Anti-Climactic End to the Era of Randomized Phase 3 Trials of Next-Generation ALK TKIs in the Crizotinib-Refractory Setting

  2023influential citation
• Synthesis and clinical application of small-molecule inhibitors and PROTACs of anaplastic lymphoma kinase.

  2023cites this paper
• Anaplastic lymphoma kinase inhibitors—a review of anticancer properties, clinical efficacy, and resistance mechanisms

  2023cites this paper
• Lorlatinib as a first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: Α cost-effectiveness analysis in Greece

  2023cites this paper
• Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy

  2022cites this paper
• Phase Ib/II study of ceritinib in combination with ribociclib in patients with ALK-rearranged non-small cell lung cancer.

  2022cites this paper
• Efficacy and safety exposure–response analyses of entrectinib in patients with advanced or metastatic solid tumors

  2022cites this paper
• Cancer Chemotherapy-Induced Sinus Bradycardia: A Narrative Review of a Forgotten Adverse Effect of Cardiotoxicity

  2022cites this paper
• Cost-effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for Non-small Cell Lung Cancer in Greece

  2022cites this paper
• Pretreatment Nutritional Status in Combination with Inflammation Affects Chemotherapy Interruption in Women with Ovarian, Fallopian Tube, and Peritoneal Cancer

  2022cites this paper
• Insights into the antimicrobial effects of ceritinib against Staphylococcus aureus in vitro and in vivo by cell membrane disruption

  2022cites this paper
• Safety profile of tyrosine kinase inhibitors used in non-small-cell lung cancer: An analysis from the Italian pharmacovigilance database

  2022cites this paper
• Targeting Gatekeeper Mutations for Kinase Drug Discovery.

  2022cites this paper
• A clinician's guide to bioinformatics for next-generation sequencing.

  2022cites this paper
• Protein kinase inhibitor ceritinib blocks ectonucleotidase CD39 – a promising target for cancer immunotherapy

  2022cites this paper
• Cancer treatment and drug-induced QT interval prolongation: A review

  2022cites this paper
• A review of patient-reported outcome assessments in registration trials of FDA-approved new oncology drugs (2014-2018).

  2022cites this paper
• Solvent-less Dehydrogenative C–H Etherification with Alcohols Using Mechanochemistry

  2021cites this paper
• Room-Temperature Amination of Chloroheteroarenes in Water by a Recyclable Copper(II)-Phosphaadamantanium Sulfonate System.

  2021cites this paper
• Cost effectiveness of ceritinib in patients previously treated with crizotinib and chemotherapy with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) in the United States

  2021cites this paper
• Identification of novel ALK fusions using DNA / RNA sequencing in immunohistochemistry / RT-PCR discordant NSCLC patients.

  2021cites this paper
• Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer

  2021cites this paper
• Pharmacological inhibition of focal adhesion kinase 1 (FAK1) and anaplastic lymphoma kinase (ALK) identified via kinome profile analysis attenuates lipopolysaccharide-induced endothelial inflammatory activation.

  2021cites this paper
• Biomarkers and Target Therapy for Lung Cancer

  2021cites this paper
• Population pharmacokinetic analysis of entrectinib in pediatric and adult patients with advanced/metastatic solid tumors: support of new drug application submission

  2021cites this paper
• Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States

  2021cites this paper
• Small Molecule Kinase Inhibitor Drugs (1995-2021): Medical Indication, Pharmacology, and Synthesis.

  2021cites this paper
• 间变性淋巴瘤激酶抑制剂不良反应管理西南专家建议（2021年版）

  2021cites this paper
• The Underlying Biology and Therapeutic Vulnerabilities of Leptomeningeal Metastases in Adult Solid Cancers

  2021cites this paper
• Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations.

  2020cites this paper
• The Role of CYP450 Drug Metabolism in Precision Cardio-Oncology

  2020cites this paper
• Oncology in the Precision Medicine Era: Value-Based Medicine

  2020cites this paper
• ALK INHIBITORS AND POSSIBLE SMALL MOLECULES OF NON-SMALL CELL LUNG CANCER: A LITERATURE REVIEW

  2020cites this paper
• Design and Characterization of Ceritinib Self-nanoemulsifying Drug Delivery Systems

  2020cites this paper
• Relationship between cardiac arrhythmias and anticancer therapy

  2020cites this paper
• Liquid biopsy mutation panel for non-small cell lung cancer: analytical validation and clinical concordance

  2020cites this paper
• Retrospective Observational Study of ALK-Inhibitor Therapy Sequencing and Outcomes in Patients with ALK-Positive Non-small Cell Lung Cancer

  2020cites this paper
• Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis

  2020influential citation
• Biomarkers from Bench to Bedside and Back – Back‐Translation of Clinical Studies to Preclinical Models

  2020cites this paper
• A Comprehensive Review of Clinical Cardiotoxicity Incidence of FDA-Approved Small-Molecule Kinase Inhibitors

  2020cites this paper
• Liquid Biopsy: The Unique Test for Chasing the Genetics of Solid Tumors

  2020cites this paper
• Arrhythmogenic Anticancer Drugs in Cardio-Oncology.

  2019cites this paper
• The incidence of ALK inhibitor-related pneumonitis in advanced non-small-cell lung cancer patients: A systematic review and meta-analysis.

  2019cites this paper
• Meta-analysis comparing incidence of grade 3-4 neutropenia with ALK inhibitors and chemotherapy in patients with non-small-cell lung cancer.

  2019cites this paper
• Arrhythmias in Cancer Patients

  2019cites this paper
• Novel derivatives of anaplastic lymphoma kinase inhibitors: Synthesis, radiolabeling, and preliminary biological studies of fluoroethyl analogues of crizotinib, alectinib, and ceritinib.

  2019cites this paper
• Empirical evaluation of the implementation of the EMA guideline on missing data in confirmatory clinical trials: Specification of mixed models for longitudinal data in study protocols

  2019cites this paper
• 12-25-2018 Targeted Therapies for Advanced Non-Small Cell Lung Cancer

  2019cites this paper
• Drug discovery targeting anaplastic lymphoma kinase (ALK).

  2019cites this paper
• Straightforward Electrochemical Sulfonylation of Arenes and Aniline Derivatives using Sodium Sulfinates

  2019cites this paper
• Chinese perspectives on clinical efficacy and safety of alectinib in patients with ALK-positive advanced non-small cell lung cancer

  2019influential citation
• Emerging therapies for non-small cell lung cancer

  2019cites this paper
• Ceritinib‐associated hyperglycemia in the Japanese Adverse Drug Event Report Database

  2019cites this paper
• Lung Cancer

  2019cites this paper
• Skin adverse events in recently approved targeted therapies in solid malignancies.

  2019cites this paper
• Meta-analysis of overall incidence and risk of ALK inhibitors-induced liver toxicities in advanced non-small-cell lung cancer

  2019cites this paper
• Safety and Tolerability of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer

  2019cites this paper
• Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study.

  2019cites this paper
• Management of Locally Advanced Lung Cancer

  2019cites this paper
• Personalized genomic medicine: non-small-cell lung cancer and anaplastic lymphoma kinase

  2019cites this paper
• Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer.

  2019cites this paper
• Application of time-dependent modeling for the exposure–efficacy analysis of ceritinib in untreated ALK-rearranged advanced NSCLC patients

  2019cites this paper
• Molecularly Targeted Therapy for Neuroblastoma

  2018cites this paper
• Ceritinib Aggravates Glycemic Control in Insulin-treated Patients with Diabetes and Metastatic ALK-positive Lung Cancer

  2018cites this paper
• ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer.

  2018cites this paper
• Efficacy and safety of crizotinib in patients with anaplastic lymphoma kinase-positive advanced-stage non-small-cell lung cancer

  2018cites this paper
• Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials

  2018cites this paper
• Inhibition of Collagen Related Peptide Induced Platelet Activation and Apoptosis by Ceritinib

  2018cites this paper
• Latest perspectives of orally bioavailable 2,4-diarylaminopyrimidine analogues (DAAPalogues) as anaplastic lymphoma kinase inhibitors: discovery and clinical developments

  2018cites this paper
• Targeted therapies for advanced non-small cell lung cancer

  2018cites this paper
• Treatment patterns, clinical and economic outcomes of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer receiving ceritinib: a retrospective observational claims analysis

  2018cites this paper
• Electrophysiologic Toxicity of Chemoradiation

  2018cites this paper
• ALK in Neuroblastoma: Biological and Therapeutic Implications

  2018cites this paper
• Pneumonitis after precision oncology therapies: A concise review

  2018cites this paper
• FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non‐Small Cell Lung Cancers Harboring BRAF V600E Mutations

  2018cites this paper
• Induction of anaplastic lymphoma kinase (ALK) as a novel mechanism of EGFR inhibitor resistance in head and neck squamous cell carcinoma patient-derived models

  2018cites this paper
• Clinical Pharmacokinetics of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer

  2018cites this paper
• Evolution strategy of ROS1 kinase inhibitors for use in cancer therapy.

  2018cites this paper
• Bruton’s tyrosine kinase potentiates ALK signaling and serves as a potential therapeutic target of neuroblastoma

  2018cites this paper
• New developments in brain metastases

  2018cites this paper
• Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors

  2018cites this paper
• Patient-reported outcomes in a phase II study of alectinib

  2018cites this paper